Determinants of Achieving Serum Urate Goal with Treat‐to‐Target Urate‐Lowering Therapy in Gout
Arthritis & Rheumatology · 2024
DOI: 10.1002/art.42731 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Arthritis & Rheumatology, 2024. Verfasst von Lindsay N Helget und 13 weiteren Autor:innen. Beteiligte Einrichtung: Veterans Affairs (VA) Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha. Hauptthemen laut MEDLINE: Allopurinol, Gout. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: CSRD VA, NCATS NIH HHS, NIGMS NIH HHS.
Abstract (Originalsprache)
Objective
Using trial data comparing treat‐to‐target allopurinol and febuxostat in gout, we examined participant characteristics associated with serum urate (SU) goal achievement.
Methods
Participants with gout and SU ≥6.8 mg/dL were randomized to allopurinol or febuxostat, titrated during weeks 0 to 24, and maintained weeks 25 to 48. Participants were considered to achieve SU goal if the mean SU from weeks 36, 42, and 48 was
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Veterans Affairs (VA) Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha.
- VA Boston Cooperative Studies Program Coordinating Center, Boston, Massachusetts.
- VA Boston Cooperative Studies Program Coordinating Center and Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts.
- VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, New Mexico.
- VA New York Harbor Health Care System and New York University Grossman School of Medicine, New York.
- Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts.
ORCID-Profile: Lindsay N Helget, Bryant R England, Michael H Pillinger, Tuhina Neogi, Ted R Mikuls
Förderung
- CSRD VA
- NCATS NIH HHS
- NIGMS NIH HHS
- NIH HHS
- VA
- BLRD VA
- NIAMS NIH HHS
- CSP VA
Zitieren
APA
Helget, L. N., O'Dell, J. R., Newcomb, J. A., Androsenko, M., Brophy, M. T., Davis-Karim, A., England, B. R., Ferguson, R., Pillinger, M. H., Neogi, T., Palevsky, P. M., Wu, H., Kramer, B., & Mikuls, T. R. (2024). Determinants of Achieving Serum Urate Goal with Treat‐to‐Target Urate‐Lowering Therapy in Gout. Arthritis & Rheumatology. https://doi.org/10.1002/art.42731
Vancouver
Helget LN, O'Dell JR, Newcomb JA, Androsenko M, Brophy MT, Davis-Karim A, et al. Determinants of Achieving Serum Urate Goal with Treat‐to‐Target Urate‐Lowering Therapy in Gout. Arthritis & Rheumatology. 2024. doi:10.1002/art.42731
BibTeX
@article{Helget2024,
author = {Helget, Lindsay N and O'Dell, James R and Newcomb, Jeff A and Androsenko, Maria and Brophy, Mary T and Davis-Karim, Anne and England, Bryant R and Ferguson, Ryan and Pillinger, Michael H and Neogi, Tuhina and Palevsky, Paul M and Wu, Hongsheng and Kramer, Bridget and Mikuls, Ted R},
title = {Determinants of Achieving Serum Urate Goal with Treat‐to‐Target Urate‐Lowering Therapy in Gout},
journal = {Arthritis & Rheumatology},
year = {2024},
doi = {10.1002/art.42731}
}
EUVIMED